Annual Pain & Migraine Therapeutics Summit

Start

Wed, 19 Oct 2016, 07:30

End

Thu, 20 Oct 2016, 02:45

WebSite

http://paintherapeuticsummit.com/

Hashtag:

#Painsummit

Venue:

Exhibit

Symposia

Workshops

Organiser

Sponsor

ARROWHEAD’S ANNUAL PAIN & MIGRAINE THERAPEUTICS SUMMIT is the US’s premier pain conference covering the field of pain research and therapeutics. Leaders from the pharmaceutical, biotech, device and medical communities attend this conference to learn about the latest advances in the treatment of various types of pain and to network with colleagues from industry, the non-profit sector, academia, the medical community, government and investors.

This conference provides attendees with thoughtful insight from key industry leaders and academic researchers concerning cutting edge drug discovery science, preclinical development trends, analysis of key clinical-stage pain therapies and newly marketed products. We will highlight the most important developments in recent years in the field, including new research in genome-wide association studies, CGRP antagonists, NGF antagonists, sodium and calcium channel blockers, new research in biologic therapies, the genetic components of pain, abuse-resistant opioids, analysis of FDA’s REMS program and a plethora of other topics.

KEY THEMES

• Analysis of new drug discovery targets

• Real-time fMRI (functional magnetic resonance imaging) for pain

• Analysis of NGF antagonist clinical development programs

• Challenges of pain clinical trials

• Endpoints in pain clinical trials

• Gene therapy for pain

• Abuse-resistant opioids in clinical development

• Genome-wide associations studies of pain

• Sodium and calcium channel blockers in pre-clinical & clinical development

• The future role of pharmacogenomics, biomarkers and translational research in the development of therapeutics for pain

• Analysis and case studies of successful commercialization strategies for pain therapies

Industry Rate

Early Bird (through August 20, 2016): $1695
Regular Rate (after August 20, 2016): $1995

Academic/Health Care Provider/Government

Early Bird (through August 20, 2016): $695
Regular Rate (through August 20, 2016): $895

Student Rate
Early Bird (through August 20, 2016): $300
Regular Rate (through August 20, 2016): $400

NOTE: Arrowhead reserves the right to verify affiliation and qualification for all rates.

To Register Click Here

AGENDA

DAY ONE - OCTOBER 19, 2016

7:30 am	Registration/Continental Breakfast
8:10 am	Chairperson's Opening Remarks
	William K. Schmidt, Ph.D., President, NorthStar Consulting, LLC, VP Clinical & Regulatory, Centrexion
	Corp., Chief Medical Officer, Signature Therapeutics, VP Clinical Development, EicOsis, LLC
8:15 am	Imaging-based Pain Neurosignatures
8:45 am	Exploring the Interplay between Rescue Drugs, Data Imputation and Study Outcomes in Analgesic Clinical Trials
9:15 am	Pain Policies and Predicaments: Who is to Blame and What are the Real Solutions?
9:45 am	Morning Break/Exhibiting Viewing/Poster Session Viewing
10:10 am	Pain, Policies and Predicaments - Follow-Up Panel Discussion
11:00 am	Kappa Opioid Receptor Agonists (KORA’s) A Novel Approach to Managing Acute and Chronic Pain
11:30 am	An Exploratory Clinical Phase 2 Study With a Dual Inhibitor on 5HT2A and GlyT2 in Postoperative pPain
12:00 pm	Luncheon
1:00 pm	Clinical Development of a Novel Opioid Molecule with Inherent Anti-abuse Properties, Less Sedation and Less Respiratory Depression
1:30 pm	A Novel Endomorphin Analog Providing Pain Relief Comparable to Morphine with Substantially Reduced Side Effects
2:00 pm	Chasing Men on Fire: Sodium Channels and Pain, from Squid to Clinic
2:30 pm	Intrathecal Substance P-Saporin for the Treatment of Intractable Cancer Pain
3:00 pm	Afternoon Refreshment Break/Exhibit Viewing/Poster Viewing
3:25 pm	Is There a Future for Fatty Acid Amide Hydrolase Inhibitors in Neuropathic Pain?
3:55 pm	Agonists for the A3 Subtype of Adenosine Receptor are Potent Analgesics for Neuropathic Pain and Adjuncts that Improve Opiate Analgesic Therapy
4:25 pm	An Open Dialogue and Q&A with the Day's Presenters
5:10 pm	Cocktail Reception

DAY TWO - OCTOBER 20, 2016

7:45 am	Continental Breakfast
8:30 am	Ricolinostat, a Clinical Stage HDAC6 Inhibitor, Induces a Rapid, Persistent Reversal of Established Peripheral Neuropathic Pain in Rodent Models
9:00 am	AYX1, An EGR1 Decoy Oligonucleotide, Provides Long-term Reduction of Postoperative Pain and Prevention of Chronic Pain After TKA
9:30 am	The Integration of Artificial and Human Intelligence for Differentiated Pain Therapeutics
10:00 am	Morning Refreshment Break/Exhibit Viewing/Poster Viewing
10:25 am	Panel Session: Transformational Change in Pain and Migraine
11:15 am	Implementing Central Statistical Surveillance in Clinical Trials
11:45 am	Voltage Gated Na Channels as Targets for Pain Therapy - Is there Light at the End of the Tunnel?
12:15 pm	Luncheon
1:15 pm	Translational Pain Medicine - The Future for Reverse Translation
1:45 pm	An Open Dialogue and Q&A with the Day's Presenters
2:45 pm	End of Conference